#	Pagina
attuale pagina	/open-h2020/projects/224134/index.html
-1	/open-h2020/projects/199936/index.html
-2	/open-h2020/per-topic/formalized/list/index.html
-3	/open-h2020/projects/210372/deliverables.html
-4	/open-h2020/per-topic/morgera/list/index.html
-5	/open-h2020/per-topic/intensive/list/index.html
-6	/open-consip/fornitori/2021/profilo-02585540921/index.html
-7	/open-consip/fornitori/2021/profilo-02637520921/index.html
-8	/open-consip/fornitori/2021/profilo-06043370821/index.html
-9	/open-consip/fornitori/2021/profilo-02785290921/index.html
-10	/open-h2020/projects/199578/index.html

Opendata, web and dolomites

AB-DiRecT SIGNED

Antibiotic Distribution and Recovery in Tissue

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

AB-DiRecT project word cloud

Explore the words cloud of the AB-DiRecT project. It provides you a very rough idea of what is the project "AB-DiRecT" about.

antimicrobials microdialysis tonsil treat oral agents action pk surgery treatment gonorrhoea tonsillectomy ab gonorrhoeae elective explore burden trials positive prostate pathogens gsk poppk understand exposure acute requiring undergoing difference dose tract healthcare direct single healthy penetration imposes fluoroquinolones antimicrobial resistance discovery mechanism classes levels plasma data conduct gepotidacin pkpd explored sites threat first pharyngeal infected triazaacenaphthylene economic tissue broad subjects uncomplicated prostatectomy antibacterial models antibiotics caused efficacy gram regimens determinants contemporary model determined active class vitro clinical prostatitis health urgent isolates antibacterials animal pbpk selective infections body urinary coli urogenital negative provision resistant infection

Project "AB-DiRecT" data sheet

The following table provides information about the project.

Coordinator	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	3˙789˙717 €
EC max contribution	3˙429˙217 € (90%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2018-16-single-stage
Funding Scheme	IMI2-RIA
Starting year	2019
Duration (year-month-day)	from 2019-07-01 to 2021-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	1˙234˙278.00
2	MEDIZINISCHE UNIVERSITAET WIEN MEDIZINISCHE UNIVERSITAET WIEN Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 website: www.meduniwien.ac.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (WIEN)	participant	1˙116˙375.00
3	CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS Organization address address: RUE DE LA MILETRIE 2 city: POITIERS CEDEX postcode: 86021 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (POITIERS CEDEX)	participant	539˙188.00
4	INSERM - TRANSFERT SA INSERM - TRANSFERT SA Organization address address: RUE WATT 7 city: PARIS postcode: 75013 website: www.inserm-transfert.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	335˙625.00
5	CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS Organization address address: BOULEVARD TONELLE 2 city: TOURS CEDEX 9 postcode: 37044 website: www.chu-tours.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (TOURS CEDEX 9)	participant	203˙750.00
6	GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. Organization address address: Great West Road 980 city: BRENTFORD postcode: TW89GS website: www.gsk.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (BRENTFORD)	participant	0.00

Map

Project objective

Antimicrobial resistance imposes an important health and economic burden with the threat of a future without effective antibiotics requiring major changes to contemporary healthcare provision. Therefore, the discovery and development of novel mechanism of action agents able to treat resistant infections is a key urgent need. Gepotidacin is a first in class, novel triazaacenaphthylene antibacterial that is being developed by GSK. Due to its novel mechanism of action, gepotidacin is active in vitro against most target pathogens carrying resistance determinants to established antibacterials, including fluoroquinolones. Gepotidacin has broad gram-positive activity and selective gram-negative activity and is currently under development as a treatment for infections caused by N. gonorrhoeae (urogenital gonorrhoea) and E. coli (acute uncomplicated urinary tract infections), including isolates resistant to existing classes of antimicrobials. To explore the potential of gepotidacin to treat infections caused by N. gonorrhoeae or E. coli at other body sites, the AB-DiRecT consortium will conduct a tissue distribution study in tonsil and prostate after single oral dose of gepotidacin in healthy (non-infected) subjects undergoing elective tonsillectomy or prostatectomy. Microdialysis will be used to measure gepotidacin levels in tissue following surgery and PBPK, PopPK and PKPD models will be built to understand the tissue penetration of gepotidacin to characterize exposure response and to evaluate different dose regimens. Difference between infected and healthy tissue will be explored in an animal prostatitis infection model where gepotidacin PK in plasma and tissue will be determined using microdialysis. Overall the data generated in AB-DiRecT may support the potential for clinical trials to determine the efficacy of gepotidacin for the treatment for pharyngeal N. gonorrhoeae infections and / or prostatitis caused by E. coli.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AB-DIRECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AB-DIRECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

VITAL (2019)

Vaccines and Infectious Diseases in the Ageing PopuLation

Read More

WEB-RADR 2 (2018)

WEB-RADR 2

Read More

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More